Form 4: Valor IV Pharma Distributes Harmony Biosciences Shares

Valor IV Pharma Holdings, LLC has completed an in-kind pro rata distribution of 6.6 million Harmony Biosciences common shares to its underlying entities and individuals.

Summary

• Valor IV Pharma Holdings, LLC distributed 6,618,033 shares of Harmony Biosciences Holdings, Inc. common stock on August 28, 2025.
• This transaction was an in-kind pro rata distribution, meaning shares were transferred to existing owners without additional consideration.
• Following the distribution, Valor IV Pharma Holdings, LLC directly holds 0 shares of Harmony Biosciences.
• Shares were distributed to various Valor entities and individuals, including Valor Management L.P. (29,497 shares), Antonio Gracias (437,619 shares), AJG Growth Fund LLC (50,423 shares), Juan Sabater (38,275 shares), and Tamal, LLC (23,714 shares).
• Antonio Gracias and Juan Sabater, both directors and 10% owners of Harmony Biosciences, disclaim beneficial ownership of the shares previously held by Valor IV Pharma Holdings, LLC.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The transaction is a routine distribution by an investment vehicle, not a direct sale into the market. It clarifies ownership structure, which can be seen as a positive for transparency, but also sets the stage for potential future sales by the new direct holders.

Positives

• The distribution clarifies the ultimate beneficial ownership of a significant block of shares, potentially increasing transparency for investors.
• The transaction was an in-kind distribution rather than a direct sale into the open market, which typically avoids immediate downward pressure on the stock price from the transaction itself.

Negatives

• The distribution could precede future sales by the new direct holders, potentially increasing selling pressure on the stock over time.
• The complex ownership structure and the disclaimer of beneficial ownership by directors, while legally standard, might be perceived as less straightforward by some investors.

Risks

• Future sales by the entities and individuals who received shares in the distribution could impact Harmony Biosciences' stock price.
• A shift in direct ownership structure might lead to changes in voting power or influence over the company's strategic decisions, depending on the intentions of the new direct holders.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Management Comments

• Antonio Gracias and Juan Sabater, each a director of Harmony Biosciences, may be deemed to share beneficial ownership over the shares of the Issuer held by Valor IV Pharma Holdings, LLC by virtue of their positions with Valor entities; however, each disclaims beneficial ownership of these shares.

Industry Context

This transaction represents a common practice for private equity firms or investment vehicles to distribute holdings to their limited partners or underlying funds, rather than a direct response to broader industry trends. It is an internal restructuring of ownership within the Valor group.

Comparison to Industry Standards

• In-kind distributions are a standard practice for private equity funds or investment vehicles when they are winding down a specific fund or distributing assets to their limited partners. This is a common method for large shareholders to divest without a direct market sale.
• The disclaimer of beneficial ownership by directors (Gracias and Sabater) is a standard legal practice in SEC filings where individuals hold positions in multiple entities that collectively own shares, used to clarify their direct versus indirect control and avoid misattribution.

Corporate Governance

Related Party Transactions

• The in-kind distribution of shares from Valor IV Pharma Holdings, LLC to various Valor-related entities and individuals (including directors Antonio Gracias and Juan Sabater) constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The distribution itself does not immediately impact the share price, but it shifts a large block of shares to new direct holders who may have different selling intentions, potentially affecting future stock liquidity and price.
• Management: The clarification of ownership structure may provide greater clarity on the influence of key investors and directors.

Next Steps

• The entities and individuals who received shares in the distribution may decide to hold or sell their newly acquired shares in the future, which could impact market liquidity and share price.

Key Dates

Recommendation

This Form 4 filing details a routine in-kind distribution of shares by an investment vehicle. It is not a market sale and does not inherently signal a change in the company's fundamentals or immediate prospects. While it clarifies ownership and could precede future sales, it does not provide a strong basis for a 'buy' or 'sell' recommendation based solely on this disclosure. Investors should continue to evaluate Harmony Biosciences based on its operational performance, financial results, and broader market conditions.

Keywords

Harmony Biosciences, HRMY, Valor IV Pharma, Valor Management, Antonio Gracias, Juan Sabater, SEC Form 4, beneficial ownership, stock distribution, insider transaction, 10% owner